**Ethiopia**

**Population 2018**

<table>
<thead>
<tr>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total TB incidence</strong></td>
<td>165 (116–223) 151 (107–204)</td>
</tr>
<tr>
<td><strong>HIV-positive TB incidence</strong></td>
<td>7.6 (5.3–10) 7 (4.9–9.4)</td>
</tr>
<tr>
<td><strong>MDR-RR-TB incidence</strong></td>
<td>1.6 (1–2.2) 1.4 (0.96–2)</td>
</tr>
<tr>
<td><strong>HIV-negative TB mortality</strong></td>
<td>24 (15–36) 22 (14–33)</td>
</tr>
<tr>
<td><strong>HIV-positive TB mortality</strong></td>
<td>2.2 (1.5–3) 2 (1.4–2.8)</td>
</tr>
</tbody>
</table>

**Estimated proportion of TB cases with MDR/RR-TB, 2018**

- % tested with rapid diagnostics at time of diagnosis
- % with known HIV status
- % pulmonary
- % bacteriologically confirmed
- % children aged 0-14 years
- % women
- % men

**Universal health coverage and social protection**

- **TB treatment coverage (notified/estimated incidence), 2018**: 69% (51–98)
- **TB patients facing catastrophic total costs**
- **TB case fatality ratio (estimated mortality/estimated incidence), 2018**: 17% (9–25)
- **TB/HIV care in new and relapse TB patients, 2018**
  - Number (%)
    - on antiretroviral therapy

**Drug-resistant TB care, 2018**

- % of bacteriologically confirmed TB cases tested for rifampicin resistance
  - New cases
  - Previously treated cases

**Laboratory-confirmed cases**

- MDR/RR-TB: 741, XDR-TB: 3
- MDR/RR-TB: 747, XDR-TB: 3

**Treatment success rate and cohort size**

- **New cases registered in 2017**: 96% 113 690
- **Previously treated cases registered in 2017**
- **MDR-RR-TB cases started on second-line treatment in 2016**: 72% 703
- **XDR-TB cases started on second-line treatment in 2016**

**TB preventive treatment, 2018**

- % of HIV-positive people (newly enrolled in care) on preventive treatment
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

**TB financing, 2019**

- National TB budget (US$ millions): 94
  - 11% domestic, 29% international, 60% unfunded

---

*Ranges represent uncertainty intervals

**MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

**Calculated for pulmonary cases only

*Includes cases with unknown previous TB treatment history

**Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

---

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2020-02-25

Data: www.who.int/tb/data